COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

215 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-06

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

COVID-19 infection is currently confirmed by a complex, multiple-step procedure starting with a mucosal swab, followed by viral RNA extraction and processing and qPCR.

This study aims to explore a novel method using machine learning and artificial intelligence (AI) algorithm to diagnose COVID-19 infection through the morphological analysis of lymphocyte subset in the peripheral blood. This study will also risk stratify patients with COVID 19 infection based on the above finding along with other clinical, haematological and biochemical parameters with a view to predict clinical outcome with high sensitivity and specificity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FAst and SimplE COVID-19 Causing Virus SARS-CoV-2 Detection

NCT05341635

COVID-19

COMPLETED

COVID-19 Clinical Status Associated With Outcome Severity: An Unsupervised Machine Learning Approach

NCT05119465

COVID-19

COMPLETED

Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease

NCT04779359

COVID-19 Disease

UNKNOWN

Rapid Detection of COVID-19 by Portable and Connected Biosensor

NCT04367142

Sars-CoV2

COMPLETED

COVID Breath Test - Ancon

NCT04760639

Covid19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational study which will be carried out at East Suffolk and North Essex NHS Foundation Trust (ESNEFT) in collaboration with University of Suffolk (UoS).

Investigators aim to analyse subsets of lymphocytes in the prospective blood smear slides using machine learning and AI algorithm obtained from participants with a positive qPCR test for COVID-19 who have required a hospital admission. The control group will consist of archived blood smear slide data from patients both with i) non-suspected viral infections, and ii) those with a non-COVID-19 viral infection obtained prior to the emergence of COVID-19 infection in the United Kingdom. In total, 785 blood smear slides will be analysed. The aim of this study is to establish the diagnosis of COVID 19 infection based on lymphocyte morphology on patients with COVID-19 infection from other patients with non COVID -19 viral infections. A high definition single cell lymphocyte image from patients with COVID 19 infection and control group will be analysed using open source histopathology imaging software CellProfiler against very fine cytoplasmic and nuclear details of the cells through supervised and unsupervised machine learning algorithm to identify recurring pattern that is unique to COVID 19 infection. The study will also assess other relevant clinical, haematological and biochemical parameters in conjunction with the above morphological features to develop a risk stratification tool to predict the clinical outcome of patients with COVID-19 infection with high specificity and sensitivity using bioinformatics pipeline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 COVID SARS-CoV 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID 19 group

The COVID 19 group will consist of peripheral blood smear slides from patients who are in the hospital who had qPCR results positive for COVID-19.

No interventions assigned to this group

CONTROL group

A control group will consist of i) peripheral blood smear slides from patients with no viral infection and ii) from those with a non-SARS-CoV-2 viral infection. Control group peripheral blood slides will be randomly selected from the laboratory slides archive within the facility. The laboratory slides used will be inclusive of slides archived prior to the emergence of COVID-19 infection in the United Kingdom.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female or male participants
* Aged over 18 years old (no upper age limit)
* Patients with SARS-COV-2 positive diagnosis based on qPCR (Study COVID 19 group)
* Peripheral blood smear slides from patients with no viral infection, reposited in the laboratory slides archive within the facility prior to the emergence of COVID-19 infection in the United Kingdom (Control group)
* Peripheral blood smear slides from patients with a non-SARS-CoV-2 viral infection that were reposited in the laboratory slides archive within the facility prior to the emergence of COVID-19 infection in the United Kingdom (Control group).

Exclusion Criteria

* Patients that are less than 18 years old
* Patients with SARS-COV-2 negative diagnosis based on qPCRPatients who have been haematological malignancies with lymphocytosis as predominant manifestation.
* Patients who have lymphopenia in the past due to underlying inflammatory disorders.
* Patients who have lymphopenia due to previous cytotoxic or immunosuppressive therapy.
* Positive diagnosis of Human Immunodeficiency Virus (HIV).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No